ICCC Q2 2022 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-15.0% YoY

Gross Profit

$2M44.2% margin

Operating Income

-$619,007-16.0% margin

Net Income

-$684,148-17.7% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

-35.6%

Cash Flow

Operating Cash Flow

$373,458

Free Cash Flow

-$569,832

Stock-Based Comp.

$61,634

Balance Sheet

Total Assets

$46M

Total Liabilities

$13M

Stockholders' Equity

$33M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$5M	-15.0%
Gross Profit	$2M	$2M	-17.7%
Operating Income	-$619,007	$215,508	-387.2%
Net Income	-$684,148	$141,113	-584.8%